Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Aug 31, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020	Nov 30, 2019
Net Income	-176.98	-143.95	-180.36	-117.19	-43.24	-21.7
Depreciation & Amortization	14.48	12.25	9.61	5.28	2.18	2.35
Other Amortization	1.4	1.4	1.2	0.8	-	-
Loss (Gain) From Sale of Assets	0.01	0.56	0.01	0.13	-	-
Loss (Gain) From Sale of Investments	-9.76	-5.42	0.43	1.71	0.27	-0.11
Stock-Based Compensation	33.45	33.67	28.13	15.8	4.3	0.51
Other Operating Activities	0.29	-	0.2	-	-	-
Change in Accounts Receivable	2	-	6	-6	-7.5	-
Change in Accounts Payable	2.27	1.61	0.09	1.59	1.23	0.3
Change in Unearned Revenue	35.58	19.51	-26.63	14.25	48.18	16.89
Change in Income Taxes	-	-	-	3.64	-3.85	-
Change in Other Net Operating Assets	0.12	-1.01	1.52	-4.37	-1.66	2.36
Operating Cash Flow	-97.14	-81.37	-159.81	-84.37	-0.08	0.6
Capital Expenditures	-9.75	-8.4	-12.24	-5.66	-4.55	-1.65
Investment in Securities	-121.52	76.7	39.44	-102.59	-249.85	10.15
Investing Cash Flow	-131.27	68.3	27.2	-108.25	-254.4	8.5
Issuance of Common Stock	285.17	3.22	22.43	164.13	239.42	0.14
Other Financing Activities	-0.02	-	94.76	-10.24	-20.65	-0.02
Financing Cash Flow	285.15	3.22	117.19	153.88	339.02	0.13
Net Cash Flow	56.74	-9.85	-15.42	-38.73	84.54	9.23
Free Cash Flow	-106.9	-89.77	-172.05	-90.03	-4.63	-1.05
Free Cash Flow Margin	-189.45%	-116.60%	-445.42%	-302.61%	-26.00%	-3.37%
Free Cash Flow Per Share	-1.75	-1.65	-3.54	-2.10	-0.30	-0.32
Cash Income Tax Paid	-	-	-	0.48	0	0
Levered Free Cash Flow	-56.77	-41.93	-79.35	-37.7	-25.94	-29.4
Unlevered Free Cash Flow	-56.77	-41.93	-79.35	-37.7	-25.94	-29.4
Change in Net Working Capital	-24.72	-16.06	-8.8	-19.76	-12.75	16.71

Source: S&P Capital IQ. Standard template. Financial Sources.